SEC Form 4 · accession 0001562180-16-003207
Akebia Therapeutics, Inc. · AKBA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michel Dahan
Officer — SVP, Chief Business Officer
Period of report
Oct 1, 2016
Accepted (ET)
Oct 4, 2016 · 4:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001517022
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Oct 1, 2016 | S | 1,401 | $8.9548 | D | 72,153 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares sold by reporting person to pay taxes in connection with the vesting of restricted stock pursuant to a December 23, 2013 award. Twenty-five percent of the shares vested on December 2, 2014, and the remaining shares vest in equal quarterly installments through December 2, 2017.